CoChat

A Randomized Double-blind Placebo-controlled Trial on the Effect of Magnesium Oxide in Patients With Chronic Constipation

Open access

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

BACKGROUND/AIMS: Magnesium oxide (MgO) has been frequently used as a treatment for chronic constipation (CC) since the 1980s in Japan. The aim of this study is to evaluate its therapeutic effects of MgO in Japanese CC patients. METHODS: We conducted a randomized, double-blind placebo-controlled study. Thirty-four female patients with mild to moderate constipation were randomly assigned to either placebo (n = 17) or MgO group (n = 17) 0.5 g × 3/day for 28 days. Primary endpoint was overall improvement over the 4-week study period. Secondary endpoints were changes from baseline in spontaneous bowel movement (SBM), response rates of complete spontaneous bowel movement (CSBM), stool form, colonic transit time (CTT), abdominal symptom, and quality of life. RESULTS: = 0.003). CONCLUSION: Our placebo-controlled study demonstrated that MgO was effective treatment for improving defecation status and shortened CTT in Japanese CC patients with mild to moderate symptoms.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.5056/jnm18194

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Study design.
Figure 1 Study design.CC BY-NC · PubMed Central
Figure 2 Patient’s flowchart summary.
Figure 2 Patient’s flowchart summary.CC BY-NC · PubMed Central
Figure 3 Effect of overall symptomatic improvement in Japanese patients with chronic constipation. (A) Weekly average value of overall improvement score. (B) Response rate of overall improvement. Compared to the response rate of 25.0% for overall symptom improvement in the placebo group, that with magnesium oxide (MgO) was significantly higher at 70.6%.
Figure 3 Effect of overall symptomatic improvement in Japanese patients with chronic constipation. (A) Weekly average value of overall improvement score. (B) Response rate of overall improvement. Compared to the response rate of 25.0% for overall symptom improvement in the placebo group, that with magnesium oxide (MgO) was significantly higher at 70.6%.CC BY-NC · PubMed Central
Figure 4 Changes of spontaneous bowel movement (SBM) and Bristol stool form scale (BSFS) after magnesium oxide (MgO) treatment in Japanese patients in chronic constipation. (A) Weekly average value of SBM and its change from baseline. (B) Weekly average value of complete spontaneous bowel movement (CSBM) and the response rate of CSBM. (C) Weekly average of BSFS score and its change from baseline.
Figure 4 Changes of spontaneous bowel movement (SBM) and Bristol stool form scale (BSFS) after magnesium oxide (MgO) treatment in Japanese patients in chronic constipation. (A) Weekly average value of SBM and its change from baseline. (B) Weekly average value of complete spontaneous bowel movement (CSBM) and the response rate of CSBM. (C) Weekly average of BSFS score and its change from baseline.CC BY-NC · PubMed Central
Figure 5 Effect of magnesium oxide (MgO) on gastrointestinal symptoms in Japanese patients with chronic constipation. (C) The severity score for straining during defecation in the placebo group did not differ before versus after taking the drug, although there was significant improvement in the MgO group (P = 0.003). The 2 groups did not show any statistically significant differences in terms of (A) abdominal bloating, (B) abdominal discomfort, or (D) sensation of incomplete evacuation.
Figure 5 Effect of magnesium oxide (MgO) on gastrointestinal symptoms in Japanese patients with chronic constipation. (C) The severity score for straining during defecation in the placebo group did not differ before versus after taking the drug, although there was significant improvement in the MgO group (P = 0.003). The 2 groups did not show any statistically significant differences in terms of (A) abdominal bloating, (B) abdominal discomfort, or (D) sensation of incomplete evacuation.CC BY-NC · PubMed Central
Figure 6 Change of quality of life ([A] short form-8 [SF-8] and the [B] Japanese version of the patient assessment of constipation quality of life [JPACQOL]) in Japanese patients with chronic constipation. The 2 groups also showed no differences in physical component summary (PCS) score and mental component summary (MCS) score. JPAC-QOL evaluations indicated that the degree of change in the total score before versus after the intervention was significantly higher in the magnesium oxide (MgO) group than in the placebo group.
Figure 6 Change of quality of life ([A] short form-8 [SF-8] and the [B] Japanese version of the patient assessment of constipation quality of life [JPACQOL]) in Japanese patients with chronic constipation. The 2 groups also showed no differences in physical component summary (PCS) score and mental component summary (MCS) score. JPAC-QOL evaluations indicated that the degree of change in the total score before versus after the intervention was significantly higher in the magnesium oxide (MgO) group than in the placebo group.CC BY-NC · PubMed Central
Figure 7 Change in the constipation scoring system (CSS) score in Japanese patients with chronic constipation. While administration of magnesium oxide (MgO) significantly improved defecation status, we did not observe any improvement in the placebo group (P = 0.018).
Figure 7 Change in the constipation scoring system (CSS) score in Japanese patients with chronic constipation. While administration of magnesium oxide (MgO) significantly improved defecation status, we did not observe any improvement in the placebo group (P = 0.018).CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Research works printed but not linked: 3

  1. 10.1111/j.1572-0241.1999.922_a.x · doi:10.1111/j.1572-0241.1999.922_a.x · Paper page
  2. Ministry of Health, Labour and Walfare. Hypermagnesaemia caused by magnesium oxide. Pharmaceuticals and Medical Devices Safety Information 2015;328:5-8 Available from URL: https://www.pmda.go.jp/english/safety/info-services/drugs/medical-safety-information/0013.html. (accessed 3 Sep 2019).
  3. Sakimura K, Machino H, Miyoshi K, et al. Clinical evaluation of YO-106 (magnesium oxide tablets) in the treatment of habitual constipation–a cross over study with magnesium oxide powders. Jpn Pharmacol Ther 1998;26:1027-1053.

Cited by

See all 47

Metadata

Authors
Mori, S., Tomita, T., Fujimura, K., Asano, H., Ogawa, T., Yamasaki, T., Kondo, T., Kono, T., Tozawa, K., Oshima, T., Fukui, H., Kimura, T., Watari, J., & Miwa, H.
Affiliations
Hyogo Medical University (JP)
Corresponding author
Tomita, Toshihiko
Venue
Journal of Neurogastroenterology and Motility
Published
2019-10-30
Volume
25
Issue
4
Pages
563-575
ISSN
  • 2093-0879 (ISSN-L)
  • 2093-0887
OpenAlex
W2978309347
Cited by
47
References
40
Citations by year
2026: 7 · 2025: 9 · 2024: 8 · 2023: 7 · 2022: 7 · 2021: 6 · 2020: 2
FWCI
3.42
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Journal of Neurogastroenterology and Motility (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Urology › Pelvic floor disorders treatments
  • Health Sciences › Medicine › Surgery › Congenital gastrointestinal and neural anomalies
Keywords
magnesium oxide, chronic constipation, colonic transit time, spontaneous bowel movements, stool consistency, abdominal symptoms, quality of life, Japanese patients

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Randomized Double-blind Placebo-controlled Trial on the Effect of Magnesium Oxide in Patients With Chronic Constipation. https://app.cochat.ai/papers/10.5056/jnm18194
The paper
Mori, S., Tomita, T., Fujimura, K., Asano, H., Ogawa, T., Yamasaki, T., Kondo, T., Kono, T., Tozawa, K., Oshima, T., Fukui, H., Kimura, T., Watari, J., & Miwa, H. (2019). A Randomized Double-blind Placebo-controlled Trial on the Effect of Magnesium Oxide in Patients With Chronic Constipation. Journal of Neurogastroenterology and Motility. https://doi.org/10.5056/jnm18194

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.